Patents by Inventor Gauthier J.P. Deblonde

Gauthier J.P. Deblonde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chelating platform for delivery of radionuclides
    Patent number: 11235076
    Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: February 1, 2022
    Assignees: Fred Hutchinson Cancer Research Center, The Regents of the Universitv of California
    Inventors: Roland K. Strong, Peter Rupert, Rebecca J. Abergel, Ilya Captain, Gauthier J P Deblonde
  • SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION
    Publication number: 20190287691
    Abstract: Provided herein are separation processes for metal ions present in aqueous solutions based on methods involving liquid-liquid extraction. The separation process involves a chelator that can selectively bind to at least one of the metals at a relatively low pH. This can be used, for example, for recovery and purification of actinides from lanthanides, separation of metal ions based on their valence, and separation of metal ions based on the pH of the extraction conditions.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 19, 2019
    Inventors: Rebecca J. ABERGEL, Roland K. STRONG, Gauthier J.P. DEBLONDE, Abel RICANO
  • FORMULATIONS AND TREATMENTS EMPLOYING HYDROXYPYRIDONATE ACTINIDE/LANTHANIDE DECORPORATION AGENTS
    Publication number: 20190183868
    Abstract: Provided herein are methods for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent to a subject in need of such treatment. The subject can be one who has been, or will be, exposed to one or more known or unknown actinides and/or lanthanides, or a mixture thereof.
    Type: Application
    Filed: May 2, 2017
    Publication date: June 20, 2019
    Inventors: Rebecca J. Abergel, Gauthier J.P. Deblonde